Single Patient Use of ION-682884 for a Patient with Transthyretin Mediated Amyloid Cardiomyopathy
N
Noel Dasgupta
Primary Investigator
Enrolling By Invitation
18-100 years
All
Phase
N/A
1 participants needed
1 Location
Overview
This study is being done to help potentially improve or stabilize heart failure related to transthyretin amyloidosis. The plan is to administer this investigational drug (ION-682884) 45 mg subcutaneously every 4 weeks.
Description
Amyloid Cardiomyopathy
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Amyloid Cardiomyopathy
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria:
- Patient with transthyretin-mediated amyloid cardiomyopathy who have been approved by the FDA and Indiana University IRB for single IND (compassionate use) of ION-682884.
Exclusion Criteria:
Updated on
10 May 2024.
Study ID: 11464, PATH-IIR-ION-682884-EA
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
